Published in J Virol on July 01, 2000
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med (2005) 3.63
Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology (2009) 1.78
Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J Virol (2007) 1.61
CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules. J Exp Med (2002) 1.49
CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One (2012) 1.48
Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium. PLoS One (2012) 1.43
Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog (2011) 1.27
Epitope-specific TCRbeta repertoire diversity imparts no functional advantage on the CD8+ T cell response to cognate viral peptides. Proc Natl Acad Sci U S A (2008) 1.24
Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. J Virol (2008) 1.14
Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest (2013) 1.12
The hypervariable immunodominant NP418-426 epitope from the influenza A virus nucleoprotein is recognized by cytotoxic T lymphocytes with high functional avidity. J Virol (2006) 1.09
Altered function in CD8+ T cells following paramyxovirus infection of the respiratory tract. J Virol (2005) 1.09
Effective simian immunodeficiency virus-specific CD8+ T cells lack an easily detectable, shared characteristic. J Virol (2009) 1.01
Dose-dependent modulation of CD8 and functional avidity as a result of peptide encounter. Immunology (2007) 1.01
Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation. J Immunol (2011) 0.98
A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge. Vaccine (2011) 0.97
Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines. PLoS One (2010) 0.97
Age-related appearance of a CMV-specific high-avidity CD8+ T cell clonotype which does not occur in young adults. Immun Ageing (2008) 0.95
T cell sensitivity and the outcome of viral infection. Clin Exp Immunol (2009) 0.92
High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment. PLoS One (2012) 0.91
CD8αα Expression Marks Terminally Differentiated Human CD8+ T Cells Expanded in Chronic Viral Infection. Front Immunol (2013) 0.90
Cutting edge: Dendritic cells prime a high avidity CTL response independent of the level of presented antigen. J Immunol (2008) 0.86
In vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity. Mol Ther (2010) 0.83
Changes in functional but not structural avidity during differentiation of CD8+ effector cells in vivo after virus infection. J Immunol (2012) 0.83
Nuclear localization of avian polyomavirus structural protein VP1 is a prerequisite for the formation of virus-like particles. J Virol (2004) 0.80
Increased sensitivity to antigen in high avidity CD8(+) T cells results from augmented membrane proximal T-cell receptor signal transduction. Immunology (2011) 0.80
αβ TCR-mediated recognition: relevance to tumor-antigen discovery and cancer immunotherapy. Cancer Immunol Res (2015) 0.78
Structural and functional correlates of enhanced antiviral immunity generated by heteroclitic CD8 T cell epitopes. J Immunol (2014) 0.78
Developing Combined HIV Vaccine Strategies for a Functional Cure. Vaccines (Basel) (2013) 0.77
CD4+ T cell subset differentiation and avidity setpoint are dictated by the interplay of cytokine and antigen mediated signals. PLoS One (2014) 0.77
Forward Vaccinology: CTL Targeting Based upon Physical Detection of HLA-Bound Peptides. Front Immunol (2014) 0.77
Escape is a more common mechanism than avidity reduction for evasion of CD8+ T cell responses in primary human immunodeficiency virus type 1 infection. Retrovirology (2011) 0.76
Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses. Vaccines (Basel) (2014) 0.75
In vivo modulation of avidity in highly sensitive CD8(+) effector T cells following viral infection. Viral Immunol (2013) 0.75
Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity (1998) 17.27
Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol (1983) 14.36
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 12.07
Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (1998) 11.08
Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol (1981) 9.86
MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell (1994) 6.92
CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med (1999) 6.06
Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med (1996) 4.70
A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science (1995) 4.64
Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol (1989) 4.17
Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature (1999) 4.13
Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A (1996) 4.11
Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes. Nature (1991) 3.80
Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med (1999) 3.64
Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A (1993) 3.27
Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol (1997) 3.24
Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med (1993) 2.96
Molecular characterization of the human macrophage mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells. J Exp Med (1990) 2.85
A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today (1996) 2.67
Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J Exp Med (1990) 2.58
Inhibition of murine T cell-mediated cytolysis and T cell proliferation by a rat monoclonal antibody immunoprecipitating two lymphoid cell surface polypeptides of 94 000 and 180 000 molecular weight. Eur J Immunol (1982) 2.47
Immunology. Licence to kill. Nature (1998) 2.34
Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. EMBO J (1993) 2.25
MHC class I-restricted CTL responses to exogenous antigens. Immunity (1996) 2.12
Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol (1994) 2.10
Liposome-encapsulated antigens are processed in lysosomes, recycled, and presented to T cells. Cell (1991) 1.81
The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur J Immunol (1997) 1.64
An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself. J Exp Med (1990) 1.54
In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help. J Immunol (1991) 1.51
Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies. J Exp Med (1991) 1.47
Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med (1992) 1.36
Priming of influenza virus-specific cytotoxic T lymphocytes vivo by short synthetic peptides. J Immunol (1991) 1.36
In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. J Immunol (1996) 1.33
Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus. Proc Natl Acad Sci U S A (1997) 1.28
Biodegradable microspheres as a vaccine delivery system. Mol Immunol (1991) 1.24
Biodegradable microparticles as controlled release antigen delivery systems. Immunology (1991) 1.24
Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci U S A (1997) 1.23
Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. J Immunol (1994) 1.20
CD4-independent in vivo priming of murine CTL by optimal MHC class I-restricted peptides derived from intracellular pathogens. Int Immunol (1995) 1.19
Modulation of immunogenicity and antigenicity of proteins by maleylation to target scavenger receptors on macrophages. J Immunol (1995) 1.13
Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J Immunol (1993) 1.11
Attenuated Mengo virus: a new vector for live recombinant vaccines. J Virol (1995) 1.09
Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion. J Virol (1993) 1.04
Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol (1996) 1.03
Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses. Eur J Immunol (1995) 1.00
A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur J Immunol (1998) 0.97
In vivo priming of cytotoxic T lymphocyte responses in relation to in vitro up-regulation of major histocompatibility complex class I molecules by short synthetic peptides. Eur J Immunol (1992) 0.95
Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine (1996) 0.93
Processing of exogenous heat-aggregated (denatured) and particulate (native) hepatitis B surface antigen for class I-restricted epitope presentation. J Immunol (1995) 0.91
Lack of Th1 or Th2 polarization of CD4+ T cell response induced by particulate antigen targeted to phagocytic cells. Int Immunol (1997) 0.88
Induction of cytotoxic T-cell response by optimal-length peptides does not require CD4+ T-cell help. Immunology (1996) 0.81
Activation of B cells by 1 microm particulate lysozyme or peptides: a Th-dependent pathway requiring CD40-CD40 ligand interaction. Int Immunol (1998) 0.80
Recombinant hepatitis B surface antigen as a carrier of human immunodeficiency virus epitopes. Res Virol (1993) 0.79
Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol (2006) 57.72
PIQA: pipeline for Illumina G1 genome analyzer data quality assessment. Bioinformatics (2009) 6.17
Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol (1989) 4.17
An epidemiological study of disorders in late childhood and adolescence--I. Age- and gender-specific prevalence. J Child Psychol Psychiatry (1993) 3.54
Has evidence changed practice?: appropriateness of carotid endarterectomy after the clinical trials. Neurology (2007) 2.75
Adolescent suicide attempters. Response to suicide-prevention programs. JAMA (1990) 2.40
Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev (2000) 2.20
Single H2Kb, H2Db and double H2KbDb knockout mice: peripheral CD8+ T cell repertoire and anti-lymphocytic choriomeningitis virus cytolytic responses. Eur J Immunol (1999) 2.15
The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J Exp Med (2001) 2.12
Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun (1996) 1.98
Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine (2000) 1.97
Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol (1985) 1.82
Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun (1998) 1.79
Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet (1993) 1.79
Molecular detection and in vivo analysis of the specific T cell response to a protein antigen. Eur J Immunol (1992) 1.75
In vivo persistence of a HIV-1-encoded HLA-B27-restricted cytotoxic T lymphocyte epitope despite specific in vitro reactivity. Eur J Immunol (1991) 1.72
An improved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smokers' lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res (1992) 1.62
In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help. J Immunol (1991) 1.51
Circulating antibodies to mouse laminin in Chagas disease, American cutaneous leishmaniasis, and normal individuals recognize terminal galactosyl(alpha 1-3)-galactose epitopes. J Exp Med (1987) 1.49
B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. J Immunol (2001) 1.45
A mouse carcinoembryonic antigen gene family member is a calcium-dependent cell adhesion molecule. J Biol Chem (1991) 1.45
Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. CMAJ (1997) 1.44
T-immunogenic peptides are constituted of rare sequence patterns. Use in the identification of T epitopes in the human immunodeficiency virus gag protein. Eur J Immunol (1988) 1.43
Carrier-induced epitopic suppression is initiated through clonal dominance. J Immunol (1989) 1.41
[Is ketamine useful for anesthesia in morbid obesity?]. Ann Fr Anesth Reanim (2001) 1.38
In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. J Immunol (1996) 1.33
The macrophage, target cell of the synthetic adjuvant muramyl dipeptide. Eur J Immunol (1978) 1.33
Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein. Gene (1991) 1.32
Antibodies to laminin in American cutaneous leishmaniasis. Infect Immun (1984) 1.32
Attenuated Listeria monocytogenes as a live vector for induction of CD8+ T cells in vivo: a study with the nucleoprotein of the lymphocytic choriomeningitis virus. Int Immunol (1995) 1.30
Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus. Proc Natl Acad Sci U S A (1997) 1.28
Identification of a T-cell epitope adjacent to neutralization antigenic site 1 of poliovirus type 1. J Virol (1991) 1.28
Expression of Escherichia coli beta-galactosidase in Mycobacterium bovis BCG using an expression system isolated from Mycobacterium paratuberculosis which induced humoral and cellular immune responses. Mol Microbiol (1992) 1.27
Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway. J Virol (2000) 1.27
Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci U S A (1997) 1.23
Detection of the 70-kilodalton histoplasma capsulatum antigen in serum of histoplasmosis patients: correlation between antigenemia and therapy during follow-up. J Clin Microbiol (1999) 1.21
Charge-dependent translocation of Bordetella pertussis adenylate cyclase toxin into eukaryotic cells: implication for the in vivo delivery of CD8(+) T cell epitopes into antigen-presenting cells. Proc Natl Acad Sci U S A (1998) 1.19
Cell-invasive activity of epitope-tagged adenylate cyclase of Bordetella pertussis allows in vitro presentation of a foreign epitope to CD8+ cytotoxic T cells. Infect Immun (1995) 1.17
Delivery of CD8(+) T-cell epitopes into major histocompatibility complex class I antigen presentation pathway by Bordetella pertussis adenylate cyclase: delineation of cell invasive structures and permissive insertion sites. Infect Immun (2000) 1.15
Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T cell epitope. J Immunol (1999) 1.13
Immunogenic Gal alpha 1----3Gal carbohydrate epitopes are present on pathogenic American Trypanosoma and Leishmania. J Immunol (1989) 1.13
Characterization of T-cell immune responses of Echinococcus multilocularis-infected C57BL/6J mice. Parasite Immunol (1996) 1.13
Direct delivery of the Bordetella pertussis adenylate cyclase toxin to the MHC class I antigen presentation pathway. J Immunol (1999) 1.11
Polycyclic aromatic hydrocarbon-DNA adducts in humans: relevance as biomarkers for exposure and cancer risk. Mutat Res (1998) 1.10
Mesenchymal stem cells and inflammatory lung diseases. Panminerva Med (2009) 1.09
Attenuated Mengo virus: a new vector for live recombinant vaccines. J Virol (1995) 1.09
Immune recognition of AIDS virus antigens by human and murine cytotoxic T lymphocytes. J Immunol (1988) 1.07
Defecation practices of young children in a Peruvian shanty town. Soc Sci Med (1999) 1.07
Lymphocytic choriomeningitis virus in southern France: four case reports and a review of the literature. Eur J Epidemiol (1997) 1.06
Cytotoxic T lymphocytes in HIV-induced disease: implications for therapy and vaccination. Immunodefic Rev (1989) 1.06
Immunomagnetic selection of purified monocyte and lymphocyte populations from peripheral blood mononuclear cells following cryopreservation. Clin Diagn Lab Immunol (1997) 1.06
Systemic infection of Leishmania tropica (major) in various strains of mice. Trans R Soc Trop Med Hyg (1981) 1.06
Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen. Vaccine (1993) 1.03
In vivo treatment with recombinant IL-12 protects C57BL/6J mice against secondary alveolar echinococcosis. Parasite Immunol (1998) 1.03
Genetic control of antibody responses induced against an antigen delivered by recombinant attenuated Salmonella typhimurium. Infect Immun (1994) 1.03
Antigenemia in patients with paracoccidioidomycosis: detection of the 87-kilodalton determinant during and after antifungal therapy. J Clin Microbiol (1998) 1.03
HgCl2-induced interleukin-4 gene expression in T cells involves a protein kinase C-dependent calcium influx through L-type calcium channels. J Biol Chem (1997) 1.02
Occupational exposure to airborne mercury during gold mining operations near El Callao, Venezuela. Int Arch Occup Environ Health (2001) 1.02
Epitopic suppression in synthetic vaccine models: analysis of the effector mechanisms. Cell Immunol (1987) 1.02
Weak TCR stimulation induces a calcium signal that triggers IL-4 synthesis, stronger TCR stimulation induces MAP kinases that control IFN-gamma production. Eur J Immunol (2001) 1.01
Evidence of anti-benzo[a]pyrene diolepoxide-DNA adduct formation in human colon mucosa. Carcinogenesis (1996) 1.01
Expression of heterologous peptides at two permissive sites of the MalE protein: antigenicity and immunogenicity of foreign B-cell and T-cell epitopes. Gene (1992) 1.00
In vivo regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetyl-muramyl-L-alanyl-D-isoglutamine, muramyl dipeptide for MDP. Cell Immunol (1979) 1.00
Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice. Vaccine (1995) 1.00
Studies on visceral Leishmania tropica infection in BALB/c mice. I. Clinical features and cellular changes. Clin Exp Immunol (1981) 0.99
The cellular location of a foreign B cell epitope expressed by recombinant bacteria determines its T cell-independent or T cell-dependent characteristics. J Immunol (1991) 0.98
Blind subjects process auditory spectral cues more efficiently than sighted individuals. Exp Brain Res (2004) 0.98
The in vivo elimination of CD4+ T cells prevents the induction but not the expression of carrier-induced epitopic suppression. J Immunol (1990) 0.98
Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis. Infect Immun (2000) 0.98
The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell Immunol (1997) 0.98
Disseminated histoplasmosis and human immunodeficiency virus type 1 infection: risk factors in Guatemala. Clin Infect Dis (1997) 0.98
Extending the CD4(+) T-cell epitope specificity of the Th1 immune response to an antigen using a Salmonella enterica serovar typhimurium delivery vehicle. Infect Immun (2000) 0.97
Chronic production of interferon in carrier mice congenitally infected with lymphocytic choriomeningitis virus. Virology (1982) 0.97
Influence of MDP and of some analogous synthetic glycopeptides on the in vitro mouse spleen cell viability and immune response to sheep erythrocytes. Cell Immunol (1978) 0.97
A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur J Immunol (1998) 0.97
Lactobacillus fermentum BCS87 expresses mucus- and mucin-binding proteins on the cell surface. J Appl Microbiol (2009) 0.96
Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope. J Immunol (2001) 0.95
T-Cell receptor Vbeta repertoire CDR3 length diversity differs within CD45RA and CD45RO T-cell subsets in healthy and human immunodeficiency virus-infected children. Clin Diagn Lab Immunol (2000) 0.94
Antibodies to basement membrane protein nidogen in Chagas' disease and American cutaneous leishmaniasis. J Clin Microbiol (1986) 0.94
Serological activity against galactosyl-alpha(1-3)galactose in sera from patients with several kinetoplastida infections. J Clin Microbiol (1988) 0.94
Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: results from a case--control multicenter study on lung cancer patients. Environ Health Perspect (1992) 0.94
The role of arginase I in diabetes-induced retinal vascular dysfunction in mouse and rat models of diabetes. Diabetologia (2012) 0.93
DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Ann N Y Acad Sci (1995) 0.93
Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity. J Virol (2001) 0.93
Antibodies to basement membrane proteins nidogen and laminin in sera from streptococcal-related diseases and juvenile rheumatoid arthritis patients. Clin Exp Immunol (1987) 0.93
Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Vaccine (1995) 0.93
Immunogenicity of foreign peptide epitopes expressed in bacterial envelope proteins. Res Microbiol (1991) 0.93
In vivo induction of CD4+ T cell responses by antigens covalently linked to synthetic microspheres does not require adjuvant. Int Immunol (1995) 0.92
Immunogenicity of poliovirus B and T cell epitopes presented by hybrid porcine parvovirus particles. J Gen Virol (1995) 0.92
[Geographic differences in mortality from digestive tumors in Spain, 1980-1984]. Gac Sanit (1992) 0.92
Painful shoulder in the hemiplegic and unilateral neglect. Arch Phys Med Rehabil (1990) 0.92